Contact us

DAY 2

Advancing Large Molecule Drug Discovery

Nov 20th, 2025 | Amsterdam, NL

AI-POWERED DRUG DISCOVERY

Registration Time

08:00 AM - 08:45 AM

Chairperson Address

08:45 AM - 09:00 AM

Keynote 1

09:00 AM - 09:25 AM

AI-assisted Discovery Platform for Transcriptional Gene Regulation by Nuclear Small RNAs

  • Application of AI/ML models to identify functional nuclear small RNAs driving transcriptional regulation
  • Integration of predictive algorithms with experimental validation to accelerate target discovery
  • Potential for therapeutic modulation of gene expression through RNA-guided transcriptional control

Mikko Turunen

Chief Scientific Officer
RNatives Inc

KEYNOTE 2

09:25 AM - 09:45 AM

From Misfolding to Medicine: SeNostic’s Seed Cycler succussful Drug Discovery in Proteinopathies

David Allendorf

Senior Scientist Assay Development
SeNostic GmbH

SeNostic

Medical Innovations for Neurodegenerations

Joachim Glaubitz

Chief Scientific Officer
SeNostic GmbH

TOXICOLOGY & DMPK IN DRUG DEVELOPMENT

Keynote 3

09:45 AM - 10:10 AM

From junk to gems: long non-coding RNAs unlock new therapeutic horizons

  • Once considered “junk,” long non-coding RNAs are now recognized as key regulators of gene expression
  • Emerging research shows lncRNAs as promising therapeutic targets across diverse diseases
  • New technologies are enabling the translation of lncRNA discoveries into diagnostics and treatments

Alessandro Bonetti

Director
AstraZeneca

Keynote 4

10:10 AM - 10:35 AM

Predictive Biomarkers for Optimizing Therapeutic Vaccination and PD-1 Blockade in HPV-Associated Cancers

  • Identification of a biomarker predicting response to combined therapeutic vaccination and PD-1 inhibition
  • Evaluation of immune mechanisms linking biomarker expression to treatment efficacy in HPV-related tumors
  • Implications of biomarker-guided strategies for advancing personalized biologic immunotherapy

Cornelis Melief

Director
ISAbella Pharma B.V

COFFEE BREAK IN NETWORKING SESSION

10:35 AM - 10:40 AM

PRE SCHEDULE MEETINGS

Meeting 8:
10:45 AM - 11:10 AM

Meeting 9:
11:10 AM - 11:35 AM

Meeting 10:
11:35 AM - 12:00 PM

Lunch Break

12:00 PM - 01:00 PM

ADVANCEMENTS IN BIOLOGICS

Keynote 5

01:05 PM - 01:30 PM

Improving the efficiency and effectiveness by implementing the FAIR guiding principles for scientific data

  • Tools enabling FAIR data
  • Fair as a machine learning enabler
  • Benefits of FAIR in pharma

CK Ong

Director Data Product
GSK

FIRESIDE CHAT

01:30 PM - 01:50 PM

AI-tools to push the frontiers of drug repurposing

Ziaurrehman Tanoli

Principal Investigator
University of Helsinki

Markus Vähä-Koskela

Senior researcher, Team leader
Institute for Molecular
Medicine Finland (FIMM)

PROTEIN-TARGETED DRUG DISCOVERY

Keynote 6

01:50 PM - 02:15 PM

Molecular Glues for 14-3-3 Protein-Protein Interactions

  • Enabling selective modulation of client protein binding.
  • Unlocking undruggable interfaces through induced stabilization.
  • Broad therapeutic potential across cancer and CNS disorders.

Christian Ottmann

CSO
Ambagon Therapeutics

COFFEE BREAK IN NETWORKING SESSION

02:15 PM - 02:30 PM

NEW PARADIGMS IN CNS & NEUROTHERAPEUTICS

Keynote 7

02:30 PM - 02:55 PM

Breaking the Blood-Brain Barrier: Next-Gen Drug Delivery Strategies

  • Advances in nanoparticle-based, ultrasound-mediated, and exosome-driven drug transport.
  • Overcoming limitations in CNS drug penetration and targeting.
  • Case studies of successful CNS-targeted therapies.

Dr. Ewa Gajewska

Head of Product Management, SYNTHIA
Merck Group

ANTIBODY & PROTEIN ENGINEERING

Keynote 8

02:55 PM - 03:20 PM

Overcoming Resistance Mechanisms in Antibody Therapies

  • Use of bispecific and multi-specific antibodies to address antigen escape variants
  • Engineering Fc domains to enhance durability and overcome immune evasion
  • Combination strategies with checkpoint inhibitors or small molecules to prevent resistance

Manel Kraiem

Chief Development Officer (CDO)
Skymab Biotherapeutics

Keynote 9

03:20 PM - 03:45 PM

T-Cell Activation with JJP1008: A Novel Agonistic mAb in Preclinical Cancer Models

  • Investigation of JJP1008 as an agonistic monoclonal antibody enhancing T-cell activation in tumor models
  • Preclinical evaluation demonstrating robust anti-tumor immune responses mediated by JJP1008
  • Potential of JJP1008 to synergize with existing immunotherapies for improved cancer treatment outcomes.

Marcelino Arciniega Castro

Head of Structural Biology and Data Analysis
JJP Biologics

DISRUPTIVE INNOVATION IN RESEARCH & DEVELOPMENT

Keynote 10

03:45 PM - 04:10 PM

Disruptive Innovation in Research & Development

  • Leveraging emerging technologies to accelerate discovery and development cycles
  • Redesigning R&D models through cross-disciplinary collaboration and digital integration
  • Driving value creation by translating breakthrough science into transformative therapies

Dipak Amrutkar

Director Invivo Pharmacology
Saniona

CLOSING REMARKS

END OF DAY 2

COCKTAIL PARTY

END OF DAY 1